Group 1 - Boten Pharmaceutical Technology Co., Ltd. (stock code: 300363) provides comprehensive services for small molecule drugs, peptides, oligonucleotide drugs, proteins, conjugated drugs, and cell and gene therapies throughout the drug lifecycle, covering locations in China and several countries in Europe and the US [1] - The company has experienced a decline in stock price, with a cumulative drop of -3.44% over four consecutive trading days as of August 21 [1] - In the second quarter of this year, China Europe Fund's China Europe Medical Health Mixed A Fund entered the top ten shareholders of Boten Pharmaceutical, marking a new investment [1] Group 2 - The China Europe Medical Health Mixed A Fund has achieved a year-to-date return of 26.29%, ranking 1357 out of 4492 in its category [1] - The fund is managed by Guo Lan and Zhao Lei, both of whom have extensive backgrounds in biomedical engineering and finance [2][5] - Guo Lan has been with China Europe Fund since October 2014 and has managed multiple funds, while Zhao Lei joined in May 2021 and currently serves as the fund manager and head of the equity research team [4][5]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown significant growth in recent months and year-to-date [1] - As of August 21, 2025, the latest net value of the fund is 1.8954 yuan, reflecting a growth of 0.78% [1] - The fund's one-month return is 5.63%, three-month return is 20.86%, and year-to-date return is 25.65%, with respective rankings of 4196 out of 4701, 1241 out of 4632, and 1624 out of 4492 [1] Group 2 - The top ten stock holdings of the fund account for a total of 54.73%, with major positions in WuXi AppTec (10.39%), Hengrui Medicine (9.69%), and Kanglong Chemical (5.05%) [1] - The fund was established on September 29, 2016, and as of June 30, 2025, it has a total scale of 15.163 billion yuan [1] - The fund is managed by two managers: Ge Lan and Zhao Lei, with Ge Lan having a background in biomedical engineering and extensive experience in fund management [2]

Group 1 - Aoscicon has experienced a decline for four consecutive trading days, with a cumulative drop of -5.20% [1] - Beijing Aoscicon Pharmaceutical Co., Ltd. was established in 2003 and originated from one of the earliest private new drug research institutions in Jiangsu Province, Nanjing Haiguang Applied Chemistry Research Institute [1] Group 2 - The financial report indicates that the China Europe Fund's China Europe Medical Health Mixed A has entered the top ten shareholders of Aoscicon, marking a new entry in the second quarter of this year [2] - The fund has achieved a year-to-date return of 25.26%, ranking 1433 out of a total of 4493 in its category [2] Group 3 - The fund managers of China Europe Medical Health Mixed A are Ge Lan and Zhao Lei, with Ge Lan holding a Ph.D. in Biomedical Engineering from Northwestern University in the United States [5][6] - Ge Lan has been with China Europe Fund since October 2014 and has managed several funds, currently serving as the manager of China Europe Medical Health Mixed Fund since September 29, 2016 [5][6] Group 4 - Zhao Lei, another fund manager, has a master's degree and has previously worked as a researcher and co-chief analyst in the pharmaceutical and biotechnology sector [7] - Zhao Lei joined China Europe Fund in May 2021 and is currently the manager of China Europe Medical Health Mixed A and C funds, with a recent performance of 12.97% and 13.09% respectively since July 4, 2025 [7] Group 5 - China Europe Fund Management Co., Ltd. was established in July 2006, with a current structure of 25 shareholders, including significant stakes held by WP Asia Pacific Asset Management LLC and Guodu Securities Co., Ltd. [7]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown varying returns over different time frames and has a significant concentration in its top ten stock holdings [1][3]. Group 2 - The latest net value of the China Europe Medical Health Mixed Fund C is 1.8800 yuan, reflecting a decrease of 1.92%. The fund has a one-month return of 3.52%, ranking 3963 out of 4628 in its category. Over the past six months, it has achieved a return of 25.52%, ranking 653 out of 4465, and a year-to-date return of 24.63%, ranking 1493 out of 4423 [1]. - The fund's top ten stock holdings account for a total of 54.73%, with the largest positions being WuXi AppTec (10.39%), Hengrui Medicine (9.69%), and Kanglong Chemical (5.05%) among others [1]. - As of June 30, 2025, the total scale of the China Europe Medical Health Mixed Fund C is 15.163 billion yuan, managed by fund managers Ge Lan and Zhao Lei [1]. Group 3 - Ge Lan, the fund manager, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management in 2014. Zhao Lei, also a fund manager, has experience in the pharmaceutical and biotechnology sectors and joined China Europe Fund Management in 2021 [2].

Company Overview - Bid Pharma, established in 2007 and headquartered in Shanghai, focuses on the research, production, sales, and custom synthesis of pharmaceutical intermediates [1] Stock Performance - Bid Pharma has experienced a decline in stock price for five consecutive trading days, with a cumulative drop of -3.54% [1] Fund Holdings - China Europe Fund's China Europe Medical Health Mixed A is among the top ten shareholders of Bid Pharma, maintaining its position in the second quarter of this year [2] - The fund has achieved a year-to-date return of 19.65%, ranking 909 out of 4513 in its category [2] Fund Performance Comparison - The performance of China Europe Medical Health Mixed A fund shows a year-to-date increase of 19.65%, compared to the category average of 13.49% and the CSI 300 index's 5.44% [3] Fund Manager Profiles - The fund is managed by Guo Lan, who has a Ph.D. in Biomedical Engineering from Northwestern University and has been with China Europe Fund since October 2014 [4][5] - Zhao Lei, who has a master's degree and previously worked as a researcher in the pharmaceutical and biotechnology sector, joined China Europe Fund in May 2021 and became a fund manager on July 4, 2025 [6] Fund Management Details - Guo Lan has managed multiple funds and has a total fund size of 399.08 billion with a return of 106.72% [5] - Zhao Lei currently manages two funds with a total size of 308.01 billion, achieving a return of 8.02% since her appointment [6] Company Structure - China Europe Fund Management Company was established in July 2006 and has 25 shareholders, with WP Asia Pacific Asset Management LLC holding 23.30% [6]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown positive growth in recent months and has a significant allocation in leading healthcare companies [1][3]. - As of July 15, 2025, the latest net value of the fund is 1.7462 yuan, reflecting a growth of 1.28%. The fund's one-month return is 2.18%, six-month return is 18.43%, and year-to-date return is 14.30% [1]. - The fund's top ten stock holdings account for a total of 55.30%, with significant investments in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Mindray Medical (5.21%) [1]. Group 2 - The China Europe Medical Health Mixed Fund C was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan. The fund is managed by Guo Lan and Zhao Lei [1]. - Guo Lan, the fund manager, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management in 2014 [2]. - Zhao Lei, also a fund manager, has experience in the pharmaceutical and biotechnology sectors, having worked as a researcher and analyst before joining China Europe Fund Management in 2021 [2].

Group 1 - The core point of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown a recent net value increase of 0.94% but a one-month return of -0.94% [1] - The fund's three-month return is 16.34%, ranking 306 out of 1238 similar funds, while its year-to-date return is 10.10%, ranking 434 out of 1218 [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%) and WuXi AppTec (9.95%) [1] Group 2 - The China Europe Medical Health Mixed Fund C was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan [1] - The fund is managed by two key managers: Ms. Ge Lan, who has been managing it since its inception, and Ms. Zhao Lei, who took over management on July 4, 2025 [2]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown positive growth in recent months and has a significant concentration in its top ten stock holdings [1][3] - As of July 3, 2025, the latest net value of the fund is 1.6642 yuan, reflecting a growth of 1.50%. The fund's one-month return is 1.53%, six-month return is 14.38%, and year-to-date return is 10.32% [1] - The fund's top ten stock holdings account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Mindray Medical (5.21%) [1] Group 2 - The China Europe Medical Health Mixed Fund C was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan [1] - The fund manager, Ge Lan, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management in October 2014 [2]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown a recent decline in net value but positive returns over various time frames [1] - As of June 11, 2025, the latest net value of the fund is 1.6776 yuan, reflecting a decrease of 0.80%. The fund's one-month return is 10.84%, ranking 194 out of 4655 in its category. Over three months, the return is 10.66%, ranking 282 out of 4602, and year-to-date, the return is 11.21%, ranking 813 out of 4536 [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Mindray Medical (5.21%) [1] Group 2 - The China Europe Medical Health Mixed Fund C was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan. The fund manager is Ms. Ge Lan [1] - Ms. Ge Lan has a background in biomedical engineering with a Ph.D. from Northwestern University in the United States. She has held various research and fund management positions before becoming the fund manager of the China Europe Medical Health Mixed Fund C [2]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown positive growth in its net value and returns over various time frames [1] - As of June 3, 2025, the latest net value of the fund is 1.6391 yuan, with a growth of 0.96%. The fund's return over the past month is 7.34%, ranking 224 out of 4690 in its category. Over the past three months, the return is 7.88%, ranking 461 out of 4620, and since the beginning of the year, the return is 8.66%, ranking 977 out of 4568 [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Mindray Medical (5.21%) [1] Group 2 - The China Europe Medical Health Mixed Fund C was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan [1] - The fund manager, Ge Lan, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management Company in October 2014 [2]